Associations Between Periconceptional Lifestyle Behaviour Change and Adverse Pregnancy Outcomes

Veronique Y.F. Maas  
Erasmus University Medical Center

Marjolein Poels  
Research agency Care2Research

Marije Lamain-de Ruiter  
Research agency Frontida Analytics

Anneke Kwee  
University Medical Center Utrecht

Mireille N. Bekker  
University Medical Center Utrecht

Arie Franx  
Erasmus University Medical Center

Maria P.H. Koster  (m.p.h.koster@erasmusmc.nl)  
Erasmus University Medical Center

Research Article

Keywords: periconception period, lifestyle behaviours, pregnancy outcome, risk factors, preconception care

DOI: https://doi.org/10.21203/rs.3.rs-156592/v1

License: ☑️ ① This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

While the effect of prenatal exposure to unhealthy lifestyle is widely evidenced, little is known about these exposures in the periconception period. We investigated associations between periconceptional lifestyle behaviour change and adverse pregnancy outcomes.

Methods

A retrospective secondary analysis took place within a prospective multicentre cohort study in the Netherlands, including 3,684 pregnant women. Baseline characteristics and preconceptional and first-trimester lifestyle behaviours were assessed through a self-administered questionnaire. Adverse pregnancy outcomes (hypertensive disorders in pregnancy (HDP), small for gestational age (SGA), gestational diabetes (GDM) and spontaneous preterm birth (sPTB)) were reported by healthcare professionals. Data were collected between December 2012 - January 2014 and analysed between August - December 2019, using multivariate logistic regression.

Results

Overweight, and especially obese women, have the highest odds of developing any adverse pregnancy outcome (adjusted odds ratio (aOR) 1.61 (95%CI 1.31–1.99) and aOR 2.85 (95%CI 2.20–3.68), respectively), particularly HDP and GDM. Women who prenatally quit smoking had a lower odds of SGA (aOR 1.14 (95%CI 0.59–2.21)), while women who continued smoking attained higher odds (aOR 1.91 (95%CI 1.05–1.15)). Women who did not use folic acid tended to have a higher odds of developing adverse pregnancy outcomes (aOR 1.28 (95%CI 0.97–1.69)), while women who prenatally started folic acid did not (aOR 1.01 (95%CI 0.82–1.25)).

Conclusions

Our results indicate that smoking cessation, having a lower BMI and initiating folic acid supplements preconceptionally may decrease the risk of adverse pregnancy outcomes. Therefore, intervening as early as the preconception period could benefit the health of future generations.

Background

Despite major advances in clinical research and medical technology, the prevalence of adverse maternal and neonatal pregnancy outcomes, such as preeclampsia and preterm birth, has only moderately decreased over the recent decades (1). Adverse pregnancy outcomes are associated with maternal long-term effects, as hypertensive disorders of pregnancy and gestational diabetes are independently associated with an increased risk for cardiovascular disease and type II diabetes (2). Likewise, adverse neonatal outcomes, for example, preterm birth and small for gestations age (SGA), can have long term consequences among surviving infants, such as medical disabilities, impaired cognitive development, learning difficulties and behavioural- and psychological problems (3). Evidence suggests that lifestyle changes, such as reducing alcohol use and smoking, losing weight, improving fruit and vegetable consumption, can reduce the prevalence of adverse pregnancy outcomes, especially when initiated in early pregnancy or even before conception (4–6).

The periconception period, defined as the 14 weeks before and 10 weeks after conception, is a critical window with substantial impact on fetal growth and development (7). Within this period, gametogenesis, organogenesis and placental development occur. These processes are vulnerable to disturbance of epigenetic mechanisms, leading to an altered profile of embryonic gene expression that persists throughout the lifespan (8). Tobacco- and alcohol consumption are two of the most critical teratogens for prenatal development (9, 10). According to Dutch guidelines, the incidence of women who continue smoking and alcohol
consumption in at least the first trimester of pregnancy remains 7% and approximately 40%, respectively (11). Moreover, in many Western countries, up to 50% of women are overweight or obese when they become pregnant (12). The maternal metabolic environment of overweight and obese women tends to affect placental development and these women are therefore more prone to develop adverse pregnancy outcomes like gestational diabetes or pre-eclampsia (13).

Health promotion activities, such as education, advice and a general health assessment, are likely to improve pregnancy outcomes, by early identification of risk factors encouraging behavioural change (14, 15). One way to incorporate health promotion activities in maternity care is through preconception care (PCC). Several studies have aimed to implement PCC-programs and some have successfully led to an improved level of knowledge regarding PCC and subsequent improved periconceptional lifestyle behaviours (16, 17). The potential effect of periconceptional lifestyle behaviour change on reducing multiple adverse pregnancy outcomes together is yet understudied, and it has been studied only in small sample sizes (16, 18). Therefore, the objective of our study was to investigate the association between periconceptional lifestyle behaviour change and adverse pregnancy outcomes.

Methods

Design

From December 2012 through January 2014, a prospective multicentre cohort study was conducted in the central region of the Netherlands; the RESPECT (Risk EStimation for PrEgnancy Complications to provide Tailored care) study. The current study is a secondary analysis of a prospective multicentre cohort study. The initial aim of the RESPECT study was to perform an external validation and direct comparison of published prognostic models for early prediction of the risk of developing adverse pregnancy outcomes, including predictors applicable in the first trimester of pregnancy (19).

Setting

Participants were recruited in 31 midwifery practices (primary care) and six hospitals (secondary/tertiary care). All pregnant women less than 14 weeks of gestation were eligible for inclusion in the study. A detailed description of the cohort has previously been published (19, 20). The RESPECT study has been approved by the Medical Ethics Committee of the University Medical Centre Utrecht (protocol no. 12–432/C) and written informed consent was obtained from all individual participants.

Sample

In total, 4,347 pregnant women participants from the RESPECT study were assessed for eligibility. For this specific analysis, we excluded women with pregnancies complicated by chromosomal anomalies, miscarriages before 15 weeks of gestation, births prior to 18 weeks, multiple pregnancies, women who discontinued their pregnancy or were lost to follow-up. Hence, 3,684 participants were included in this specific analysis as visible in Fig. 1.

Measures

At enrolment in the first trimester of the pregnancy, women were asked to fill out a questionnaire specifically designed for this study. This self-reported questionnaire contained items on socio-demographic characteristics, lifestyle behaviours, and medical, family and obstetrical history. After birth, healthcare professionals reported the presence or absence of pregnancy outcomes through standardized forms. The definitions of lifestyle behaviours, sociodemographic characteristics and adverse pregnancy outcomes are shown in Table 1:
| Variable | Definition |
|----------|------------|
| **Lifestyle**<br>Behaviours (Self-reported) | Body mass index Kg/m² |
| | Daily fruit intake Pieces of fruit |
| | Tobacco use ≥ 1 cigarette per day (yes/no) |
| | Alcohol use ≥ 1 glass of alcohol per week (yes/no) |
| | Folic acid use Use of folic acid, either as a single supplement or as part of multivitamin preparation (yes/no) |
| | Vitamin use Use of vitamin C, vitamin D or calcium supplement either as a single supplement or as part of multivitamin preparation (yes/no) |
| **Socio-demographic characteristics**<br>(Self-reported) | Age Years |
| | Ethnicity - White: Caucasian or other Western; - Non-White: African, Hindustani, Moroccan, Turkish, Middle Eastern, Asian, other non-western, and mixed. |
| | Educational level - Low: primary education or lower level; - Medium: secondary education; - High: tertiary education or higher level. |
| | Parity - Nulliparous: women with no previous pregnancies beyond 16 weeks; - Multiparous: women with previous pregnancies beyond 16 weeks. |
| | Mode of conception - Spontaneous conception: pregnant without medical assistance; - Non-spontaneous conception: pregnant with ovulation drugs, insemination or in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). |
| **Adverse pregnancy outcomes**<br>(Reported by the healthcare provider) | Hypertensive disorder in pregnancy (HDP) Either: - Pregnancy-induced hypertension (PIH): the new onset of hypertension (≥ 140 mmHg systolic and/or ≥ 90 mmHg diastolic blood pressure) after 20 weeks gestation measured on at least two occasions four hours apart; - Pre-eclampsia (PE): PIH accompanied by proteinuria (≥ 300 mg in 24 hours), either during pregnancy or postpartum (55–57). |
| | Small for gestation age (SGA) A birth weight < 3rd percentile, based on Hoftiezer percentiles (58, 59). |
| | Gestational diabetes (GDM) The presence of either a fasting glucose level of ≥ 7.0 mmol/L (126 mg/dl) or a glucose level of ≥ 7.8 mmol/L (140 mg/dl) two hours after a 75-grams oral glucose tolerance test (26, 60, 61). |
| | Spontaneous preterm birth (sPTB) A delivery with spontaneous onset before 37 weeks of gestation (62). |
| | Composite outcome Women with one of the following complications; pregnancy-induced hypertension, pre-eclampsia, small for gestational age < p3, gestational diabetes, spontaneous preterm birth or fetal death. |

The following lifestyle behaviours were assessed both preconceptionally and in the first trimester of pregnancy: daily fruit intake, use of tobacco and alcohol, body mass index (BMI) and the use of the following supplements; folic acid, vitamin C, vitamin D,
calcium or multivitamin. A periconceptional lifestyle behaviour change was defined as the actual cessation or initiation of the specific behaviour. The use of any vitamin or calcium supplement were combined and analysed as one determinant called ‘vitamin use’. As multivitamin includes folic acid, women using multivitamin were categorized in both ‘folic acid use’ and ‘vitamin use’. BMI was calculated based on self-reported answers to questions concerning one’s height and weight before conception. Even though BMI itself is not a lifestyle behaviour, certain lifestyle behaviours such as diet or exercise can influence a person’s BMI. The following socio-demographic characteristics were assessed: age, ethnicity, educational level, parity and mode of conception. The following pregnancy outcomes were assessed: hypertensive disorder in pregnancy (HDP; either pregnancy-induced hypertension or preeclampsia), small for gestational age (SGA) defined as birth weight < 3rd percentile, gestational diabetes (GDM), and spontaneous preterm birth (sPTB). The choice for these specific pregnancy- and neonatal outcomes was based on its prevalence, the relevance for both mother and child and its need for preventive intervention early in pregnancy. Participants were classified into either having experienced an uncomplicated pregnancy or being diagnosed with any adverse pregnancy outcome, included in our composite outcome. In case of more than one adverse pregnancy outcome, women were assigned to multiple groups except when HDP occurred simultaneously with SGA since these complications are likely to coexist with each other. In case this situation occurred, women were assigned to the HDP group, women were assigned to the SGA group when SGA was the only adverse outcome.

Statistical analysis

The original dataset contained missing data for some participants; there were 1,111 cases (30.2%) with at least one missing value. A more detailed description and an assessment of these missing values can be found in the Appendix (Supplemental File 1). Missing values were imputed using multiple imputation (19, 21). All variables and outcomes were used in the imputation model and ten imputations were performed. Results shown are the results after multiple imputation. Rubin’s rules were applied to combine the results into summary estimates (22). Baseline data for all participants are presented as medians and interquartile range (IQR) for continuous variables or as numbers and percentages for categorical variables. Logistic regression analysis was performed to identify associations between lifestyle behaviours and adverse pregnancy outcomes. Crude odds ratios (OR) and accompanying 95% confidence intervals (CI) were calculated by univariate analysis. Subsequently, adjusted ORs were calculated by multivariate analysis, taking potential confounders into account (maternal age, educational level, ethnicity, parity and mode of conception). Reference categories were chosen for categorical variables based on the desired lifestyle behaviour. The statistical analysis of the data was performed in the final months of 2019, using SPSS version 25.0. P-values < 0.05 were considered statistically significant.

Results

The median age of these participants was 30.8 years (IQR 28.0-33.6) and 3,330 (90.4%) women were Caucasian (Table 2). Conception occurred spontaneously in 3,429 (93.1%) women, 2,131 (57.8%) women were highly educated and 1,643 (44.6%) women were nulliparous. The proportion of women who smoked and used alcohol preconceptionally was 20.9% (n = 771) and 60.9% (n = 2,244), respectively. The majority of these women changed their unhealthy lifestyle behaviours in the first trimester, 492 women (63.8%) quit smoking and 2,216 women (98.7%) quit drinking alcohol. A total of 2,177 (59.1%) women started using folic acid supplements preconceptionally, while 1,077 (29.2%) women started using folic acid supplement after conception took place.

Table 2. Demographics and lifestyle behaviours of study participants stratified by pregnancy outcome
| Adverse pregnancy outcome | Cohort | Uncomplicated | Composite | HDP | SGA | GDM | sPTB |
|---------------------------|--------|---------------|-----------|-----|-----|-----|------|
|                           | n=3684 | n=2972 (80.7) | n=712     | n = 298 | n=133 | n=184 | n=127 |
| Age (years)               | 30.8 (28.0-33.6) | 30.8 (27.9-33.6) | 30.8 (28.2-33.7) | 30.3 (27.6-32.9) | 30.6 (28.0-33.9) | 31.8 (29.7-34.8)* | 30.6 (28.2-32.6) |
| Ethnicity                 |        |               |           |     |     |     |      |
| Caucasian                 | 3330 (90.4) | 2706 (91.0) | 624 (87.6) | 277 (93.0) | 111 (83.5) | 144 (78.3) | 117 (92.1) |
| Non-Caucasian             | 354 (9.6) | 266 (9.0) | 88 (12.4)* | 21 (7.0) | 22 (16.5)* | 40 (21.7) | 10 (7.9) |
| Educational level         |        |               |           |     |     |     |      |
| Low                       | 279 (7.6) | 213 (7.2) | 66 (9.3)* | 20 (6.7) | 20 (15.0)* | 18 (9.8) | 11 (8.7) |
| Medium                    | 1274 (34.6) | 995 (33.5) | 279 (39.3)* | 124 (41.6)* | 49 (36.8) | 82 (44.6)* | 47 (37.0) |
| High                      | 2131 (57.8) | 1764 (59.3) | 367 (51.4) | 154 (51.7) | 64 (48.2) | 84 (45.7) | 69 (54.3) |
| Parity                    |        |               |           |     |     |     |      |
| Nullipara                 | 1643 (44.6) | 1224 (41.2) | 418 (58.8)* | 189 (63.4)* | 34 (25.6)* | 73 (39.7) | 86 (67.7)* |
| Multipara                 | 2041 (55.4) | 1748 (58.8) | 293 (41.2) | 109 (36.6) | 99 (74.4) | 110 (59.8) | 41 (32.3) |
| Mode of conception        |        |               |           |     |     |     |      |
| Spontaneous conception    | 3429 (93.1) | 2791 (93.9) | 638 (89.6) | 261 (87.6) | 120 (90.2) | 155 (84.2) | 116 (91.4) |
| Non- spontaneous conception | 255 (6.9) | 181 (6.1) | 74 (10.4)* | 37 (12.4)* | 13 (9.8) | 29 (15.8)* | 11 (8.7) |
| Pre-pregnancy BMI          |        |               |           |     |     |     |      |
| Underweight (<18.5 kg/m²) | 99 (2.7) | 81 (2.7) | 18 (2.5)* | 2 (0.7) | 9 (6.8)* | 2 (1.1) | 4 (3.1) |
| Normal weight (18.5-25 kg/m²) | 2367 (64.3) | 2001 (67.4) | 367 (51.6) | 137 (45.9) | 86 (64.6) | 67 (36.4) | 86 (67.7) |
| Overweight (25-30 kg/m²)   | 852 (23.1) | 654 (22.0) | 198 (27.8)* | 97 (32.6)* | 25 (18.8) | 57 (31.0)* | 28 (22.0) |
| Obese (>30 kg/m²)          | 366 (9.9) | 236 (7.9) | 129 (18.1)* | 62 (20.8)* | 13 (9.8) | 57 (31.0)* | 9 (7.1) |
| Smoking                   |        |               |           |     |     |     |      |
| No preconception smoking  | 2913 (79.0) | 2388 (80.3) | 526 (73.8) | 224 (75.2) | 92 (69.2) | 140 (76.1) | 86 (67.7) |
| Smoked, quit prenatal     | 492 (13.4) | 371 (12.5) | 120 (16.9)* | 53 (17.8) | 20 (15.0)* | 29 (15.8) | 26 (20.5)* |
| Smoked, did not quit prenatal | 279 (7.6) | 213 (7.2) | 66 (9.3) | 21 (7.0) | 21 (15.8) | 15 (8.2) | 15 (11.8)* |
### Alcohol use

|                              | No preconception use | Used alcohol, quit prenatal | Used alcohol, did not quit prenatal |
|------------------------------|----------------------|-----------------------------|-----------------------------------|
|                              | 1440 (39.1)          | 2216 (60.1)                 | 28 (0.8)                          |
|                              | 1139 (38.3)          | 1810 (60.9)                 | 24 (0.8)                          |
|                              | 302 (42.4)           | 406 (57.0)                  | 4 (0.6)                           |
|                              | 119 (39.9)           | 178 (59.7)                  | 1 (0.4)                           |
|                              | 55 (41.4)            | 76 (57.1)                   | 2 (1.5)                           |
|                              | 101 (54.9)           | 82 (44.6)*                  | 0 (0)                             |
|                              | 48 (37.8)            | 79 (62.2)                   | 0 (0)                             |

### Folic acid use (incl. multivitamin)

|                              | No preconception use | Only prenatal | Preconception and prenatal |
|------------------------------|----------------------|---------------|---------------------------|
|                              | 430 (11.7)           | 1077 (29.2)   | 2177 (59.1)               |
|                              | 330 (11.1)           | 879 (29.6)    | 1763 (59.3)               |
|                              | 99 (13.9)            | 198 (27.8)    | 415 (58.3)                |
|                              | 42 (14.1)            | 77 (25.8)     | 179 (60.1)                |
|                              | 20 (15.0)            | 42 (31.6)     | 71 (53.4)                 |
|                              | 27 (14.7)            | 50 (27.2)     | 107 (58.2)                |
|                              | 15 (11.8)            | 37 (29.1)     | 75 (59.1)                 |

### Vitamin use

|                              | No preconception use | Only prenatal | Preconception and prenatal |
|------------------------------|----------------------|---------------|---------------------------|
|                              | 1276 (34.6)          | 1405 (38.1)   | 1003 (27.3)               |
|                              | 998 (33.6)           | 1161 (39.0)   | 813 (27.4)                |
|                              | 279 (39.2)           | 243 (34.1)    | 190 (26.7)                |
|                              | 123 (41.3)           | 96 (32.2)     | 79 (26.5)                 |
|                              | 61 (45.8)            | 40 (30.1)     | 32 (24.1)                 |
|                              | 65 (35.3)            | 68 (37.0)     | 51 (17.7)                 |
|                              | 44 (34.6)            | 44 (34.6)     | 39 (30.7)                 |

### Fruit

|                              | Daily fruit intake <= 2 | Daily fruit intake >= 2 |
|------------------------------|-------------------------|-------------------------|
|                              | 1409 (38.2)             | 2275 (61.8)             |
|                              | 1124 (37.8)             | 1849 (62.2)             |
|                              | 285 (40.0)              | 427 (60.0)              |
|                              | 122 (40.9)              | 176 (59.1)              |
|                              | 56 (42.1)               | 77 (57.9)               |
|                              | 71 (38.6)               | 112 (60.9)              |
|                              | 46 (36.2)               | 81 (63.8)               |

HDP = hypertensive disorders in pregnancy; SGA = small for gestational age; GDM = gestational diabetes; sPTB = spontaneous preterm birth

Values are presented as median (IQR) or n (%)

Participants can have more than 1 adverse pregnancy outcome therefore the numbers do not add up

*differs significantly from the uncomplicated group, p<0.05

\[ a \] composite outcome: women with one of the following complications; HDP, SGA, GDM, sPTB or fetal death

\[ b \] women using multivitamin were categorized in both 'folic acid use' and 'vitamin use'

Table 2 also shows the demographic characteristics and lifestyle behaviours of women who experienced an uncomplicated pregnancy (n = 2,972; 80.7%) versus women who experienced an adverse pregnancy outcome: HDP (n = 298; 8.1%), SGA (n = 133; 3.6%), GDM (n = 184; 5.0%), sPTB (n = 127; 3.4%). In total 712 (19.3%) of all women experienced an adverse pregnancy outcome. These adverse pregnancy outcomes appeared significantly more often when women were non-Caucasian, were low- or medium educated, were nulliparous, had a non-spontaneous conception, were either under- or overweight or smoked preconceptionally.

Table 3 shows the associations between lifestyle behaviours and all adverse pregnancy outcomes. Overall, overweight and obese women and women who smoked preconceptionally had a lower odds of developing adverse pregnancy outcomes with an adjusted OR of 1.61 (95%CI 1.13–1.99), 2.85 (95%CI 2.20–3.68) and 1.32 (95%CI 1.03–1.71), respectively. Obese women had the
highest odds of developing GDM (aOR 6.85 (95%CI 4.39–10.710)), which persisted in overweight women, although much lower (aOR 2.38 (95%CI 1.60–3.54)). Overweight and obese women were also more likely to develop HDP (aOR 2.17 (95%CI 1.63–2.89) and 3.80 (95%CI 2.68–5.40), respectively). In contrast, women with a pre-pregnancy BMI ≤ 18.5 kg/m² had a higher odds of SGA (aOR 2.64 (95%CI 1.17–5.96). We found that women who smoked before pregnancy were more likely to experience sPTB (aOR 1.76 (95%CI 1.05–2.93)) compared to women who did not smoke preconceptionally. Women who continued to smoke during pregnancy were also more likely to give birth to an SGA neonate aOR 1.91 (95%CI 1.05–1.15), which was not the case for women who quit smoking after conception (aOR 1.14 (95%CI 0.59–2.21)). Women who consumed alcohol preconceptionally, yet discontinued in the first trimester, had a lower odds of developing GDM compared to women who were not used to drink alcohol prior to pregnancy recognition (aOR 0.65 (95% CI 0.46–0.93)). Compared to women who used folic acid supplements from the preconception period onwards, women who did not use folic acid supplements tended to have a (non-significantly) higher odds of developing adverse pregnancy outcomes (aOR 1.28 (95%CI 0.97–1.69)), while women who started folic acid supplements during pregnancy did not (aOR 1.01 (95%CI 0.82–1.25)). No associations were found between daily fruit intake or vitamin use and the development of adverse pregnancy outcomes.
## Table 3
Associations between lifestyle behaviours and adverse pregnancy outcome.

|                        | Composite (n = 712) | HDP (n = 298) | SGA (n = 133) | GDM (n = 184) | sPTB (n = 127) |
|------------------------|--------------------|---------------|---------------|---------------|---------------|
|                        | Crude OR (95% CI)  | Adjusted OR (95% CI) | Crude OR (95% CI)  | Adjusted OR (95% CI) | Crude OR (95% CI)  | Adjusted OR (95% CI) | Crude OR (95% CI)  | Adjusted OR (95% CI) | Crude OR (95% CI)  | Adjusted OR (95% CI) |
| **Pre-pregnancy BMI**  |                    |                |               |               |               |                    |                |               |               |               |
| Underweight (<18.5 kg/m²) | 1.18 (0.66–2.12)  | 1.22 (0.67–2.23) | 0.43 (0.11–1.74) | 0.44 (0.11–1.82) | 2.65 (1.23–5.74)  | 2.64 (1.17–5.96) | 0.86 (0.20–3.68) | 0.92 (0.21–4.04) | 1.07 (0.32–3.60) | 1.10 (0.32–3.79) |
| Normal weight (18.5–25 kg/m²) | ref | ref | ref | ref | ref | ref | ref | ref | ref | ref |
| Overweight (25–30 kg/m²) | 1.65 (1.35–2.03)  | 1.61 (1.31–1.99) | 2.18 (1.5–2.89) | 2.17 (1.63–2.89) | 0.89 (0.52–1.51) | 0.84 (0.48–1.46) | 2.59 (1.77–3.80) | 2.38 (1.60–3.54) | 1.01 (0.63–1.61) | 0.99 (0.61–1.60) |
| Obese (>30 kg/m²) | 2.96 (2.31–3.80)  | 2.85 (2.20–3.68) | 3.83 (2.72–5.38) | 3.80 (2.68–5.40) | 1.29 (0.67–2.50) | 1.16 (0.59–2.31) | 7.18 (4.74–10.89) | 6.85 (4.39–10.71) | 0.85 (0.37–1.93) | 0.82 (0.36–1.85) |
| **Smoking**            |                    |                |               |               |               |                    |                |               |               |               |
| no preconception use   | ref | ref | ref | ref | ref | ref | ref | ref | ref | ref |
| smoked, quit prenatal  | 1.48 (1.16–1.87)  | 1.32 (1.03–1.70) | 1.52 (1.08–2.14) | 1.33 (0.94–1.90) | 1.38 (0.75–2.53) | 1.14 (0.59–2.21) | 1.33 (0.87–2.05) | 1.24 (0.79–1.95) | 1.93 (1.19–3.13) | 1.76 (1.05–2.93) |
| smoked, did not quit prenatal | 1.41 (1.03–1.94) | 1.23 (0.86–1.75) | 1.03 (0.61–1.72) | 0.88 (0.52–1.50) | 2.47 (1.45–4.21) | 1.91 (1.05–3.42) | 1.17 (0.64–2.13) | 1.05 (0.55–2.02) | 1.91 (1.04–3.49) | 1.83 (0.91–3.65) |
| **Alcohol consumption**|                    |                |               |               |               |                    |                |               |               |               |
| no preconception use   | ref | ref | ref | ref | ref | ref | ref | ref | ref | ref |
| used alcohol, quit prenatal | 0.85 (0.70–1.02) | 0.84 (0.69–1.03) | 0.94 (0.72–1.24) | 0.87 (0.65–1.15) | 0.88 (0.60–1.31) | 0.88 (0.57–1.36) | 0.51 (0.37–0.71) | 0.65 (0.46–0.93) | 1.03 (0.71–1.51) | 0.89 (0.60–1.34) |
| used alcohol, did not quit prenatal | 0.58 (0.17–1.92) | 0.57 (0.17–1.94) | ref | ref | ref | ref | ref | ref | ref | ref |
| **Folic acid use**     |                    |                |               |               |               |                    |                |               |               |               |
| no preconception use   | ref | ref | ref | ref | ref | ref | ref | ref | ref | ref |
| only prenatal          | 1.28 (0.98–1.65)  | 1.28 (0.97–1.69) | 1.26 (0.87–1.81) | 1.48 (1.00–2.18) | 1.51 (0.86–2.63) | 1.41 (0.75–2.64) | 1.33 (0.84–2.11) | 0.97 (0.58–1.62) | 1.02 (0.54–1.92) | 1.18 (0.59–2.35) |
| only prenatal          | 0.96 (0.79–1.17)  | 1.01 (0.82–1.25) | 0.85 (0.63–1.14) | 0.95 (0.70–1.31) | 1.17 (0.77–1.76) | 1.26 (0.81–1.96) | 0.93 (0.65–1.33) | 0.96 (0.66–1.40) | 0.99 (0.65–1.50) | 1.10 (0.70–1.71) |
|                  | Composite (n = 712)<sup>a</sup> | HDP (n = 298) | SGA (n = 133) | GDM (n = 184) | sPTB (n = 127) |
|------------------|----------------------------------|---------------|---------------|---------------|----------------|
| preconception    | ref                              | ref           | ref           | ref           | ref            |
| and prenatal     | ref                              | ref           | ref           | ref           | ref            |
| Vitamin use<sup>f</sup> |                                |               |               |               |                |
| no preconception | 1.19 (0.96–1.48)               | 1.19 (0.95–1.50) | 1.26 (0.93–1.72) | 1.36 (0.99–1.87) | 1.53 (0.94–2.47) |
| use              |                                  |               |               |               |                |
| only prenatal    | 0.90 (0.72–1.11)               | 0.89 (0.72–1.12) | 0.85 (0.61–1.17) | 0.86 (0.61–1.20) | 0.87 (0.53–1.44) |
| preconception    | ref                              | ref           | ref           | ref           | ref            |
| and prenatal     | ref                              | ref           | ref           | ref           | ref            |
| Fruit            |                                  |               |               |               |                |
| daily fruit      | 0.91 (0.76–1.08)               | 0.84 (0.70–1.01) | 0.87 (0.73–1.14) | 0.79 (0.60–1.04) | 0.84 (0.58–1.21) |
| intake ≤ 2       |                                  |               |               |               |                |
| daily fruit      | ref                              | ref           | ref           | ref           | ref            |
| intake > 2       |                                  |               |               |               |                |

HDP = hypertensive disorders in pregnancy; SGA = small for gestational age; GDM = gestational diabetes; sPTB = spontaneous preterm birth; OR = odds ratio; CI = confidence interval;

<sup>a</sup> composite outcome: women with one of the following complications; HDP, SGA, GDM, sPTB or fetal death.

<sup>b</sup> adjusted for non-modifiable factors (age, ethnicity, educational level, nulliparity, spontaneous conception)

<sup>c</sup> n was too small in total population (n = 28) to calculate odds ratios

<sup>d</sup> including multivitamin use

<sup>e</sup> women using multivitamin were categorized in both ‘folic acid use’ and ‘vitamin use’

<sup>f</sup> vitamin C, vitamin D, calcium or multivitamin use

**Discussion**

This study confirms that unhealthy periconceptional lifestyle behaviours are associated with the prevalence of adverse pregnancy outcomes. Women who were obese prior to the pregnancy had the highest odds of developing adverse pregnancy outcomes, particularly HDP and GDM. These odds persisted in overweight women, although much lower. Underweight women, on the other hand, were more likely to give birth to an SGA neonate. Smoking prior to pregnancy was associated with sPTB and SGA, but, interestingly, for SGA this association did not persist when women quit smoking during the first trimester.

In accordance with previous studies, we indeed found that smoking is associated with a higher odds of sPTB and birth of SGA neonates (23–26). Although some studies showed that pregnant smokers who quit during the first-trimester are no longer at risk for sPTB, we found otherwise but this might very well be a spurious finding (27–29). On the other hand, we found that women who quit smoking in the first-trimester did have a similar odds of developing SGA compared to non-smokers, as previous studies have also suggested (25, 26, 28). Cigarette smoke contains substances that affect placental endothelial function, which can lead to the development of ischemic vascular changes impacting placental growth and functions (30). A previous systematic review showed that cessation of smoking before and shortly after becoming pregnant was not associated with SGA and this suggests that the mechanisms affecting fetal growth predominantly act in the second half of pregnancy (31). Nevertheless, smoking cessation prior to conception remains the best approach to improve health benefits.
Alcohol is suggested to lower levels of inflammation markers and endothelial dysfunction, increase insulin sensitivity, increase HDL cholesterol concentrations, which, for example, may lower the risk of type 2 diabetes mellitus and possibly also GDM (32–34). Several studies have shown that pre-pregnancy or prenatal consumption of small alcohol amounts has a mildly protective effect on preterm birth, intrauterine growth restriction and birth weight. The possible explanation provided for this paradox is the “healthy drinker effect”, in which women with poor obstetric prognosis, socio-economic status or well-being are more likely to abstain from drinking alcohol (35, 36). We indeed found that women who used alcohol preconceptionally were significantly more often Caucasian, higher educated, nulliparous, were pregnant by spontaneous conception, had a lower pre-pregnancy BMI and used more folic acid supplements compared to women who did not use alcohol preconceptionally (data not shown).

We found that women with a BMI of 25 kg/m² or more, especially women with a BMI above 30 kg/m², have the highest odds of developing adverse pregnancy outcomes. Previous meta-analyses suggest that higher amounts of preconceptional physical activity are associated with a lower risk of gestational diabetes and pre-eclampsia (37, 38). In addition, a population-based study showed that a 10% lower preconception BMI was associated with clinically meaningful risk reduction in pre-eclampsia, gestational diabetes, preterm birth, macrosomia, and stillbirth (4). A previous study showed that only 57% of pregnant women were aware of the fact that obesity increases the overall risk of pregnancy- and birth complications and that weight loss prior to the pregnancy can reduce to overall risk for complications (39). Hence, here lies an opportunity for PCC to encourage obese women to enter weight loss programs to improve their own health and the health of their future child.

Finally, our results showed that encouraging women to start folic acid supplements, after pregnancy recognition, can still benefit the health of mother and child. Although non-significant, we found a higher odds of adverse pregnancy outcomes for women who did not use folic acid supplements compared to preconceptional commencement. Although we found no difference in adverse pregnancy outcomes between women who started folic acid supplements before or during the pregnancy, it is widely evidenced that early initiation (ideally before conception) of folic acid supplements does decrease the risk for congenital malformations such as neural tube defects (40). In our study, congenital malformations were excluded from analysis and therefore we cannot provide any results regarding these outcomes.

Our results are alarming since an unhealthy diet, lifestyle behaviours and exercising pattern are progressively becoming part of Western society, including among a high percentage of women in their reproductive age (5, 6, 15). Encouraging women to develop and maintain a healthy lifestyle has long been a focus of prenatal care, while our findings support emerging evidence indicating that the preconception period might even be a better window of opportunity to address these unhealthy lifestyle behaviours. PCC is known to increase the health and well-being of prospective parents, still, the uptake of PCC-consults remains remarkably low (41). This is particularly the case for vulnerable women, who often have multiple unhealthy lifestyle behaviours and are specifically hard to reach (42). PCC-interventions often require engagement from prospective parents who are not yet thinking about becoming a parent in the future and are not yet known by maternal health services (43). Although some studies suggest that awareness of preconception health and care is low, pregnancy planning appears relatively common, indicating a missed and unexploited opportunity for intervention (44).

A possible strength of this study is that we used a large, multicentre, population-based cohort where we accounted for missing data by using multiple imputation, which decreases the risk of bias and allows to investigate multiple exposures and outcomes. Also, we distinguished lifestyle behaviours between the preconception period and the first trimester, a distinction rarely made in previous studies. A limitation of this study is the inclusion of a relatively high number of Caucasian and highly educated women. In addition, the data on lifestyle behaviours is collected by the use of self-administered questionnaires. Although this method is suggested to negatively affect the validity, we merely assessed the presence (yes/no questions) instead of frequencies of lifestyle behaviours, by which we probably have diminished the chance of over- or underreporting of behaviour (45). However, due to this method of questioning the distinction between preconception and first-trimester exposure is dependent upon women's perception of when conception occurred. Moreover, examining potential dose-response relationships was not possible and blood markers were not available to validate, for example, micronutrient or smoking status. Finally, as this study was only able to measure associations between periconceptional lifestyle behaviours and adverse pregnancy outcomes, and the sample size calculation was not performed for the current aim of this paper, results should be interpreted with caution and we recommend future research to focus on large-scale interventions to discover a possible (causal) effect.
Conclusion

Overall, our findings indicate that women should be encouraged to change unhealthy lifestyle behaviours, preferably before conception. Therefore, future research on interventions to improve awareness on the importance of PCC and the (cost)effectiveness of these interventions on pregnancy outcomes are needed. Findings from such studies could enhance the choice to start future preventive measures and interventions regarding unhealthy periconceptional lifestyle behaviours, to optimize the health of future generations.

List Of Abbreviations

aOR
adjusted odds ratio; BMI = body mass index; CI = confidence interval; GDM = gestational diabetes; HDP = hypertensive disorders in pregnancy; IQR = interquartile range; PCC = preconception care; PE = pre-eclampsia; PIH = pregnancy-induced hypertension; RESPECT study = Risk ESTimation for PRegnancy Complications to provide Tailored care; SGA = small for gestational age; sPTB = spontaneous preterm birth

Declarations

Ethics approval and consent to participate

The RESPECT study has been approved by the Medical Ethics Committee of the University Medical Centre Utrecht (protocol no. 12-432/C) and written informed consent was obtained from all individual participants. All methods were performed in accordance with the relevant guidelines and regulations confirm the Declaration of Helsinki.

Consent for publication

Not applicable

Availability of data and materials

The dataset for current study is available from the corresponding author upon reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This study has been conducted with the support of The Netherlands Organization for Health Research and Development (ZonMw), grant no. 209020004 and grant no. 209040005.

Authors' contributions

MPHK, AK, AF and the RESPECT study group were involved in writing the original RESPECT study protocol. The RESPECT study group and MLdR were involved in data collection. VYF, MP and MLdR performed the data analysis. VYF, MP and MPHK wrote the first draft of the manuscript, which was subsequently revised by MLdR, AK, MNB and AF. MPHK and AF are the guarantors of this study. All authors participated in the final approval of the manuscript.

Acknowledgements

We would like to thank all pregnant women who participated in the RESPECT study. We would like to thank the late dr. Henk van der Stel (Julius Centre for Health Sciences and Primary Care, University Medical Center Utrecht) for his contribution. We would like to thank the collaborators in the RESPECT study group: I. de Groot; I.M. Evers; F. Groenendaal; Y. Hering; A.J.M. Huisjes; C.
Kirpestein; W.M. Monincx; J.E. Siljee; A. van ’t Zelfde; C.M. van Oirschot; S. Vankan-Buitelaar; M.A.A.W. Vonk; T.A. Wiegers and J.J. Zwart.

References

1. Atrash HK, Johnson K, Adams M, Cordero JF, Howse J. Preconception care for improving perinatal outcomes: the time to act. Matern Child Health J. 2006;10(5 Suppl):S3-11.

2. Fraser A, Nelson SM, Macdonald-Wallis C, Cherry L, Butler E, Sattar N, et al. Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. Circulation. 2012;125(11):1367-80.

3. Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med. 2008;359(3):262-73.

4. Schummers L, Hutcheon JA, Bodnar LM, Lieberman E, Himes KP. Risk of adverse pregnancy outcomes by prepregnancy body mass index: a population-based study to inform prepregnancy weight loss counseling. Obstetrics and gynecology. 2015;125(1):133-43.

5. Lassi ZS, Imam AM, Dean SV, Bhutta ZA. Preconception care: caffeine, smoking, alcohol, drugs and other environmental chemical/radiation exposure. Reprod Health. 2014;11 Suppl 3:S6.

6. Dean SV, Lassi ZS, Imam AM, Bhutta ZA. Preconception care: nutritional risks and interventions. Reprod Health. 2014;11 Suppl 3:S3.

7. Steegers-Theunissen RP, Twigt J, Pestinger V, Sinclair KD. The periconceptional period, reproduction and long-term health of offspring: the importance of one-carbon metabolism. Hum Reprod Update. 2013;19(6):640-55.

8. Fleming TP, Watkins AJ, Velazquez MA, Mathers JC, Prentice AM, Stephenson J, et al. Origins of lifetime health around the time of conception: causes and consequences. The Lancet. 2018;391(10132):1842-52.

9. Murphy DJ, Mullally A, Cleary BJ, Fahey T, Barry J. Behavioural change in relation to alcohol exposure in early pregnancy and impact on perinatal outcomes—a prospective cohort study. BMC pregnancy and childbirth. 2013;13:8.

10. Kawashima A, Koide K, Ventura W, Hori K, Takenaka S, Maruyama D, et al. Effects of maternal smoking on the placental expression of genes related to angiogenesis and apoptosis during the first trimester. PloS one. 2014;9(8):e106140-e.

11. College Perinatale Zorg (Perinatal Care College). Preconceptie Indicatie Lijst (preconception indication list). 2018. https://www.kennisnetgeboortezorg.nl/wp content/uploads/2019/06/Preconceptie_Indicatie_Lijst PIL_.pdf. Accessed 15 January 2020.

12. Stephenson J, Heslehurst N, Hall J, Schoenaker DAJM, Hutchinson J, Cade JE, et al. Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health. The Lancet. 2018;391(10132):1830-41.

13. Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. Bmj. 2017;356:j1.

14. Whitworth M, Dowswell T. Routine pre-pregnancy health promotion for improving pregnancy outcomes. The Cochrane database of systematic reviews. 2009(4):CD007536-CD.

15. Zhao G, Ford ES, Tsai J, Li C, Ahluwalia IB, Pearson WS, et al. Trends in health-related behavioral risk factors among pregnant women in the United States: 2001-2009. J Womens Health (Larchmt). 2012;21(3):255-63.

16. Elsinga J, de Jong-Potjer LC, van der Pal-de Bruin KM, Le Cessie S, Assendelft WJ, Buitendijk SE. The effect of preconception counselling on lifestyle and other behaviour before and during pregnancy. Womens Health Issues. 2008;18(6 Suppl):S117-25.

17. Poels M, van Stel HF, Franx A, Koster MPH. The effect of a local promotional campaign on preconceptional lifestyle changes and the use of preconception care. The European Journal of Contraception & Reproductive Health Care. 2018;23(1):38-44.

18. Jourabchi Z, Sharif S, Lye MS, Saeed A, Khor GL, Tajuddin SHS. Association Between Preconception Care and Birth Outcomes. American journal of health promotion : AJHP. 2019;33(3):363-71.

19. Lamain-de Ruiter M, Kwee A, Naaktgeboren CA, de Groot I, Evers IM, Groenendaal F, et al. External validation of prognostic models to predict risk of gestational diabetes mellitus in one Dutch cohort: prospective multicentre cohort study. Bmj.
20. Lamain-de Ruiter M, Kwee A, Naaktgeboren CA, Louhanepessy RD, De Groot I, Evers IM, et al. External validation of prognostic models for preeclampsia in a Dutch multicenter prospective cohort. Hypertension in pregnancy. 2019;38(2):78-88.

21. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Bmj. 2009;338:b2393.

22. Rubin D. Multiple imputation for nonresponse in surveys. Wiley Online Library; 1987.

23. Shah NR, Bracken MB. A systematic review and meta-analysis of prospective studies on the association between maternal cigarette smoking and preterm delivery. Am J Obstet Gynecol. 2000;182(2):465-72.

24. McCowan LM RC, Dekker GA, et al. Risk factors for small-for-gestational-age infants by customised birthweight centiles: Data from an international prospective cohort study. BJOG. 2010 Dec;117(13):1599-607.

25. Bernstein IM, Mongeon JA, Badger GJ, Solomon L, Heil SH, Higgins ST. Maternal smoking and its association with birth weight. Obstet Gynecol. 2005;106(5 Pt 1):986-91.

26. Reeves S, Bernstein I. Effects of maternal tobacco-smoke exposure on fetal growth and neonatal size. Expert Rev Obstet Gynecol. 2008;3(6):719-30.

27. Moore E, Blatt K, Chen A, Van Hook J, DeFranco EA. Factors Associated with Smoking Cessation in Pregnancy. Am J Perinatol. 2016;33(6):560-8.

28. Polakowski LL, Akinbami LJ, Mendola P. Prenatal smoking cessation and the risk of delivering preterm and small-for-gestational-age newborns. Obstet Gynecol. 2009;114(2 Pt 1):318-25.

29. Jaddoe VW, Troe EJ, Hofman A, Mackenbach JP, Moll HA, Steegers EA, et al. Active and passive maternal smoking during pregnancy and the risks of low birthweight and preterm birth: the Generation R Study. Paediatr Perinat Epidemiol. 2008;22(2):162-71.

30. Aliyu MH, Lynch ON, Wilson RE, Alio AP, Kristensen S, Marty PJ, et al. Association between tobacco use in pregnancy and placenta-associated syndromes: a population-based study. Archives of Gynecology and Obstetrics. 2011;283(4):729-34.

31. Abraham M, Alramadhan S, Iniguez C, Duijts L, Jaddoe VW, Den Dekker HT, et al. A systematic review of maternal smoking during pregnancy and fetal measurements with meta-analysis. PLoS One. 2017;12(2):e0170946.

32. Koppes LL, Dekker JM, Hendriks HF, Bouter LM, Heine RJ. Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care. 2005;28(3):719-25.

33. Howard AA, Amstren JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med. 2004;140(3):211-9.

34. Bouthoorn SH, Silva LM, Murray SE, Steegers EA, Jaddoe VW, Moll H, et al. Low-educated women have an increased risk of gestational diabetes mellitus: the Generation R Study. Acta Diabetol. 2015;52(3):445-52.

35. Henderson J, Gray R, Brocklehurst P. Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome. Bjoeg. 2007;114(3):243-52.

36. Patra J, Bakker R, Irving H, Jaddoe VW, Malini S, Rehm J. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA)-a systematic review and meta-analyses. Bjoeg. 2011;118(12):1411-21.

37. Tobias DK, Zhang C, van Dam RM, Bowers K, Hu FB. Physical activity before and during pregnancy and risk of gestational diabetes mellitus: a meta-analysis. Diabetes Care. 2011;34(1):223-9.

38. Aune D, Saugstad OD, Henriksen T, Tonstad S. Physical activity and the risk of preeclampsia: a systematic review and meta-analysis. Epidemiology (Cambridge, Mass). 2014;25(3):331-43.

39. Nitert MD, Foxcroft KF, Lust K, Fagemo N, Lawlor DA, O’Callaghan M, et al. Overweight and obesity knowledge prior to pregnancy: a survey study. BMC Pregnancy Childbirth. 2011;11:96.

40. De-Regil LM, Fernandez-Gaxiola AC, Dowswell T, Pena-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2010(10):CD007950.
41. World Health O. Meeting to develop a global consensus on preconception care to reduce maternal and childhood mortality and morbidity: World Health Organization Headquarters, Geneva, 6–7 February 2012: Meeting report. 2013.

42. M'Hamdi H I, van Voorst SF, Pinxten W, Hilhorst MT, Steegers EA. Barriers in the Uptake and Delivery of Preconception Care: Exploring the Views of Care Providers. Matern Child Health J. 2017;21(1):21-8.

43. Barker M, Dombrowski SU, Colbourn T, Fall CHD, Kriznik NM, Lawrence WT, et al. Intervention strategies to improve nutrition and health behaviours before conception. Lancet. 2018;391(10132):1853-64.

44. Stephenson J, Patel D, Barrett G, Howden B, Copas A, Ojukwu O, et al. How do women prepare for pregnancy? Preconception experiences of women attending antenatal services and views of health professionals. PloS one. 2014;9(7):e103085-e.

45. Gollenberg AL, Mumford SL, Cooney MA, Sundaram R, Louis GM. Validity of retrospectively reported behaviors during the periconception window. J Reprod Med. 2011;56(3-4):130-7.

46. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension. 2018;72(1):24-43.

47. Visser GH, Eilers PH, Elferink-Stinkens PM, Merkus HM, Wit JM. New Dutch reference curves for birthweight by gestational age. Early Hum Dev. 2009;85(12):737-44.

48. Hoftiezer L, Hof MHP, Dijs-Elsinga J, Hogeveen M, Hukkelhoven C, van Lingen RA. From population reference to national standard: new and improved birthweight charts. American journal of obstetrics and gynecology. 2019;220(4):383.e1-.e17.

49. Rani PR, Begum J. Screening and Diagnosis of Gestational Diabetes Mellitus, Where Do We Stand. J Clin Diagn Res. 2016;10(4):QE01-4.

50. Lumley J. Defining the problem: the epidemiology of preterm birth. BJOG: An International Journal of Obstetrics & Gynaecology. 2003;110:3-7.